We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Persistence of islet autoantibodies after diagnosis in type 1 diabetes.
- Authors
Long, Anna E.; George, Gifty; Williams, Claire L.
- Abstract
The presence of islet autoantibodies remains a reliable biomarker to identify individuals at high risk of developing type 1 diabetes. As such, these autoantibodies play a pivotal role in understanding the prodrome of diabetes and selecting individuals for both prevention and intervention clinical trials. Over the last few decades, studies have sought to investigate autoantibody prevalence after diabetes onset to better understand ongoing islet autoimmunity; however, many findings are contradictory, and little is known about factors that may influence autoantibody persistence. Generally, glutamate decarboxylase autoantibodies (GADAs) are the most prevalent autoantibodies after diagnosis, particularly in adults, whilst zinc transporter 8 autoantibodies (ZnT8A) prevalence declines more rapidly. However, when studies with islet autoantibody data at diagnosis are considered, it becomes clear that overall islet antigen‐2 autoantibodies (IA‐2A) tend to persist for longer than GADA or ZnT8A. In this review, we assess the major studies that have contributed to our understanding of autoantibody persistence after diabetes onset and what factors affect this. Islet autoantibodies may provide biomarkers for long‐term β‐cell function and insights into how to prevent ongoing islet autoimmunity but larger studies collecting samples at and decades after diabetes onset are required to leverage the information they could provide.
- Subjects
AUTOANTIBODIES; BIOMARKERS; TYPE 1 diabetes; ISLANDS of Langerhans; RISK assessment; DISEASE risk factors
- Publication
Diabetic Medicine, 2021, Vol 38, Issue 12, p1
- ISSN
0742-3071
- Publication type
Article
- DOI
10.1111/dme.14712